GSK plc (GSK)
- Sector
- Pharmaceuticals
- Last price
- $48.74
- As of
Kresmion compiles this page from GSK's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
GSK plc (GSK): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-28.
See the full GSK dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GSK on one page. Preview it with sample data, then open it live with a free account.
Preview the GSK dossierActive events for GSK
- high13F: funds added
6 tracked funds increased GSK this 2026Q2, institutional consensus
- mediumLarge bond issue
Large debt issuance: $1.2B at 4.85% due 2029
- high13F: large reduction
CITADEL ADVISORS LLC cut 69% of GSK (2026Q2)
- high13F: funds added
3 tracked funds increased GSK this 2026Q2, institutional consensus
- high13F: large reduction
Point72 Asset Management, L.P. cut 100% of GSK (2026Q2)
FREE, NO ACCOUNT
Every event on GSK, as it fires
You are seeing 5 of 23 events recorded on GSK since 2026-05-26.
The five above landed across 3 days. The other 18 were recorded on 3 other days. 15 of the 23 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GSK (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 37733W204 · 2026Q2 | $139.1M | 0.15% | , |
| D. E. Shaw & Co., Inc.CUSIP 37733W204 · 2026Q2 | $53.4M | 0.03% | , |
| Bridgewater Associates, LPCUSIP 37733W204 · 2026Q2 | $26.4M | 0.11% | , |
| CITADEL ADVISORS LLCCUSIP 37733W204 · 2026Q2 | $7.9M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 37733W204 · 2026Q2 | $3.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GSK
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
GSK against its peers
GSK's operating margin of 24.3% ranks in the 85th percentile of 16 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-28 and 2025-12-31.
| Metric | GSK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 32.7B GBP | n/a | n/a | 0 |
| Revenue YoY | 4.1% | n/a | n/a | 3 |
| Gross margin | 72.4% | 74.3% | 47 | 15 |
| Operating margin | 24.3% | 10.5% | 85 | 16 |
| Net margin | 19.3% | 8.9% | 73 | 23 |
| Return on equity | 39.4% | 15.4% | 85 | 23 |
| P / E | n/a | 21.6x | n/a | 13 |
| 1 year | n/a | 34.0% | n/a | 10 |
Peers (25): BMY, PFE, NVO, TEVA, AZN, NVS, ZTS, MRK, VTRS, JNJ, JAZZ, CORT, LLY, AXSM, AMRX, LQDA, OGN, AMLX, TARS, BHC, SUPN, HRMY, XERS, TRVI, ANIP. Fiscal periods ending between 2025-12-28 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (GSK: 20-F), reported in GBP. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow GSK on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to GSK for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.